Project Design Phase

Proposed Solution Template

| Date | 28 JUNE 2025 | |
|---------------|--|--|
| Team ID | LTVIP2025TMID43759 | |
| Project Name | HematoVision: Advanced Blood Cell | |
| | Classification Using Transfer Learning | |
| Maximum Marks | 4 Marks | |

Proposed Solution Template:

| S.No. | Parameter | Description |
|-------|-----------------------------|--------------------------------|
| 1. | Problem Statement | Manual classification of |
| | (Problem to be solved) | blood cells under the |
| | | microscope is time- |
| | | consuming and prone to |
| | | errors, particularly in busy |
| | | pathology labs. Accurate |
| | | cell identification is crucial |
| | | for diagnosing diseases like |
| | | leukemia, infections, or |
| | | allergies. Faster, automated |
| | | solutions are needed for |
| | | better patient outcomes. |
| 2. | Idea / Solution description | We propose HematoVision, |
| | | an AI-based blood cell |
| | | classification system using |
| | | transfer learning models |
| | | (e.g., ResNet, EfficientNet). |
| | | Medical staff can upload cell |
| | | images via a web app, and |
| | | the system will predict the |
| | | cell type (Neutrophil, |
| | | Lymphocyte, Monocyte, |
| | | Eosinophil) with confidence |
| 2 | No. 11 / H. Carres | scores to assist diagnostics. |
| 3. | Novelty / Uniqueness | Uses advanced deep |
| | | learning for high accuracy. |
| | | Reduces dependence on |
| | | manual microscopy. |
| | | Trained on a specific |
| | | dataset of blood cell images. |
| | | Designed for easy adoption |
| | | by labs without complex |
| | | hardware. |

| | | Potential to expand to detect abnormal/malignant cells in future versions. |
|----|--|---|
| 4. | Social Impact / Customer Satisfaction | Improves speed and accuracy of diagnoses. Reduces workload of lab technicians. Helps early detection of blood-related disorders. Improves healthcare quality. Empowers healthcare facilities with advanced diagnostic tools. |
| 5. | Business Model (Revenue Model) | Freemium model: free basic predictions, paid advanced reports. Licensing to hospitals, diagnostic labs, or healthtech firms. Subscription-based access for larger institutions. Potential partnerships with medical device companies. API services for integration into existing lab systems. |
| 6. | Scalability of the Solution | Easily deployable on local hospital systems or cloud. Expandable to classify more cell types (e.g., blasts in leukemia). Scalable to integrate into Electronic Health Record systems. Adaptable to multiple languages and regions. Suitable for small labs or large hospitals. |